Valneva SE (VALN) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Valneva (VALN) Q1 2026: OPEX Slashed 25–35% as Lyme Uncertainty Forces Restructuring
May 13, 2026
-
Valneva (VALN) FY 2025: Proprietary Product Sales Up 9% as Lyme Vaccine Nears Phase 3 Readout
March 18, 2026
-
Valneva (VALN) Q3 2025: 12.5% Ixiaro Growth Offsets Chikungunya Setback, Lyme Catalyst Looms
November 23, 2025
-
Valneva (VALN) Q2 2025: Product Sales Jump 33% as Lyme Vaccine Milestone Nears
August 12, 2025
-
Valneva (VALN) Q1 2025: Product Sales Surge 51%, Lyme Vaccine Data Looms as Profitability Pivot
July 07, 2025